Efficacy and Safety of Modified-Dose Obinutuzumab for Refractory Membranous Nephropathy

A single-center retrospective study of 33 patients with refractory membranous nephropathy followed for up to 18 months. The dataset, authored by Jiannan Zhou and last updated in April 2026, reports on a B-cell reconstitution-guided regimen of obinutuzumab, tracking outcomes such as remission rates and safety profiles.

Use Cases

• Modeling treatment response rates based on the reported 84.8% cumulative remission rate.
• Analyzing the relationship between B-cell depletion duration and immunological remission outcomes.
• Studying safety profiles of modified-dose biologic therapies in a refractory patient population.
• Benchmarking clinical outcomes for rituximab-refractory patients against new therapeutic regimens.

Strengths

• Includes specific clinical metrics for 33 patients, such as mean 24-hour urinary protein (6.7 ± 4.9 g) and serum albumin (30.0 ± 8.3 g/L).
• Reports detailed outcome measures including a cumulative remission rate of 84.8% and a median B-cell depletion duration of 12 months.
• Clear safety profile noted, with no severe adverse events reported among the cohort.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is from a single-center retrospective study; conclusions may require validation in controlled settings as noted by the author.

Provenance

Source

figshare, authored by Jiannan Zhou.

Collection Method

Single-center retrospective study.

Time Range

Patient follow-up occurred at 3-month intervals for up to 18 months.

Freshness

Last updated 2026-04-22 05:34:54; freshness should be verified.

Geography

null